GH1 and Growth delay: In the paediatric population, NutropinAq® is licensed for the long-term treatment of growth failure due to inadequate endogenous GH secretion, the long-term treatment of girls aged ≥2 years with growth failure associated with TS, and the treatment of prepubertal children with growth failure associated with CRI up to the time of renal transplantation (18).